Dual Antiplatelet Therapy with Plavix and Aspirin
For acute coronary syndrome (ACS), dual antiplatelet therapy with clopidogrel 75 mg and aspirin 75-100 mg daily should be continued for 12 months, unless bleeding risk is excessive (PRECISE-DAPT score ≥25). 1
Primary Indications for DAPT
Acute Coronary Syndrome
- Loading strategy: Clopidogrel 600 mg loading dose (300 mg if age ≥75 years in STEMI with thrombolysis), followed by 75 mg daily 1
- Duration: 12 months mandatory for both PCI-treated and medically managed ACS patients 1, 2
- Applies to: STEMI, NSTE-ACS, and unstable angina 1
Stable Coronary Artery Disease with Stenting
- Indication: Clopidogrel 600 mg loading dose plus aspirin for patients undergoing coronary stent implantation 1
- Duration varies by stent type (though guidelines emphasize ACS gets 12 months regardless)
Aspirin Dosing During DAPT
Use aspirin 75-100 mg daily (81 mg in the US) when combined with clopidogrel 1, 2. Higher aspirin doses increase bleeding without improving efficacy and may reduce effectiveness of other P2Y12 inhibitors like ticagrelor 2.
When Clopidogrel is Specifically Recommended Over Alternatives
Clopidogrel is the P2Y12 inhibitor of choice when patients:
- Have prior intracranial bleeding 1
- Require oral anticoagulation (triple therapy scenario) 2
- Cannot receive ticagrelor or prasugrel due to contraindications 1
- Are managed medically without PCI and prasugrel is contraindicated 1
Important caveat: In ACS patients who can tolerate them, ticagrelor or prasugrel are preferred over clopidogrel for superior ischemic protection 1. However, clopidogrel remains highly effective and is the standard when more potent agents cannot be used.
Bleeding Risk Mitigation
Mandatory co-interventions during DAPT 1:
- Proton pump inhibitor (PPI) therapy - avoid omeprazole and esomeprazole which reduce clopidogrel effectiveness; use pantoprazole or rabeprazole instead 1, 3
- Radial artery access for procedures when possible
- Target INR 2.0-2.5 if warfarin needed concurrently 2
Critical Discontinuation Warnings
Do not stop DAPT within the first month after stenting for elective non-cardiac surgery 1. Premature discontinuation dramatically increases risk of stent thrombosis, myocardial infarction, and death 3. If surgery is unavoidable:
- Continue aspirin perioperatively if bleeding risk allows 1
- Resume full DAPT as soon as possible postoperatively 1
Special Populations
CYP2C19 poor metabolizers: Clopidogrel may be less effective due to reduced conversion to active metabolite 3. Consider genetic testing in high-risk scenarios, though routine testing is not recommended 1.
Triple therapy (DAPT + anticoagulation): Keep duration as short as possible; consider switching to dual therapy (anticoagulant + clopidogrel only) after initial high-risk period 2.
Evidence Strength Note
The 12-month DAPT duration for ACS is based on Class I, Level B recommendations from both 2017 ESC 1 and 2016 ACC/AHA 2 guidelines, representing the highest quality evidence. The CURE trial 3 demonstrated 20% relative risk reduction in cardiovascular death, MI, or stroke with clopidogrel-aspirin versus aspirin alone in ACS patients.
Key distinction: The CHARISMA trial showed no benefit of adding clopidogrel to aspirin in stable vascular disease patients without recent ACS 3, reinforcing that DAPT is specifically indicated for ACS and post-stenting scenarios, not for general secondary prevention.